239 results about "Anti breast cancer" patented technology

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents.

The invention relates to a collaborative anti-cancer pharmaceutical combination prediction method and a pharmaceutical composition. The collaborative anti-cancer pharmaceutical combination prediction method comprises the following steps: 1) data collection: according to different disease treatment effects of a pharmaceutical combination, classifying and obtaining a known collaborative anti-cancer pharmaceutical combination and a corresponding target; 2) model establishment: for the known collaborative anti-cancer pharmaceutical combination and an unknown pharmaceutical combination, calculating a characteristic of the collaborative anti-cancer pharmaceutical combination, and establishing a collaborative anti-cancer pharmaceutical combined prediction model; and and 3) result filtration: expressing spectrum information with the pharmacy, exploring and inducing the characteristic of the known collaborative anti-cancer pharmaceutical combination, and conducting screening with prediction results of the step 2). An anti-breast cancer pharmaceutical combination and an anti-lung cancer pharmaceutical combination can be acquired on the base of the collaborative anti-cancer pharmaceutical combination prediction method. Compared to the prior art, according to the invention, the collaborative anti-cancer pharmaceutical combination prediction method comprehensively uses various characteristics of the pharmaceutical combination, is designed dexterously, predicts accurately, has an important practical application and is suitable for large-scale popularization.

The invention discloses glycosylated boron dipyrromethene fluorophore derivatives as well as a preparation method and application of the glycosylated boron dipyrromethene fluorophore derivatives. The method comprises the following steps: by taking glucose and glucosides thereof as action targets, connecting covalent bonds of the action targets to boron dipyrromethene fluorophore derivatives for photodynamics therapy, so that a third generation photosensitizer against cancer which can be used for targeted therapy is obtained. The dipyrromethene fluorophore derivatives containing glucose and glucosides are taken as study researches, activity study of in-vitro breast cancer-resistant cells MBA-MD-231 is expanded, a prodrug suitable for molecular targeted therapy is screened, and a foundation is laid for applying the glycosylated boron dipyrromethene fluorophore derivatives to targeted therapy of cancers. Moreover, the compound synthesis method is simple, readily available in raw materials, low in cost, few in side reactions, high in yield and simple in purification, and industrial production is promoted.

The invention provides a preparation method of a double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells. The preparation method is characterized in that integrin-associated protein (CD47) and transcriptional coactivator (TAZ) are both highly expressed in breast cancer tissues, especially in the breast cancer stem cells; by established CD47 and TAZ over-expressed breast cancer cells, higher proliferation and metastasis capacity and cancer stem cell features are shown. Extracellular domain of the two breast cancer stem cell antigens CD47 and TAZ are targeted to generate monoclonal strains in specific binding under immunity action, and single-chain antibodies in specific binding with the CD47 and TAZ by genetic recombination are obtained to construct a human CD47 and TAZ containing double chimeric antigen receptor gene recombined to a virus vector to transfect human T lymphocyte. By high expression of the double chimeric antigen receptor gene in specific binding with human CD47 and TAZ expressing breast cancer stem cells, a first signal and a costimulatory signal can be activated to trigger anti-breast-cancer cytotoxicity, and high cytotoxicity in in-vivo and in-vitro anti-cancer experiments is achieved.

The invention provides a new molecular marker hsa-miR-374a of breast carcinoma, that is, non-coding RNA gene hsa-miR-374a of micromolecule as a molecular marker of breast carcinoma. Expression of the molecular marker in tissues suffering from breast carcinoma is obviously higher than that of normal mammary tissues, and is associated with clinical classification of breast carcinoma, and expression of hsa-miR-374a in breast carcinoma cell line cultured in vitro is higher than that of normal mammary epithelial cells and immortalized normal mammary epithelial cells. The invention further provides application of the molecular marker of breast carcinoma to preparing an anti-breast cancer drug. The drug comprises effective amount of blocker capable of blocking expression of non-coding RNA gene hsa-miR-374a of micromolecule. The molecular marker provides new effective way for diagnosing and treating breast carcinoma. The invention also provides certain experience and foundation for further research of function of hsa-miR-374a and relation with other tumors.

The invention belongs to the technical field of medicines, and particularly discloses an oxygen-bridge bicyclo-[2.2.1]-heptylene compound comprising N-hydroxy-N'-phenyloctanediamide (SAHA) or a like structure, wherein the oxygen-bridge bicyclo-[2.2.1]-heptylene compound has an activity of resisting breast cancer. 3-(4-hydroxy penyl)-4-octanedioic acid monoanilide-furan and a vinyl sulphonate derivative are taken as raw materials and are reacted without a solvent or a catalyst at the temperature of 90 DEG C for 3 hours to further prepare the oxygen-bridge bicyclo-[2.2.1]-heptylene compound comprising the octanedioic acid monoanilide, and then the compound is reacted with oxammonium hydrochloride to obtain the oxygen-bridge bicyclo-[2.2.1]-heptylene compound comprising the N-hydroxy-N'-phenyloctanediamide. The experiments in vitro show that the oxygen-bridge bicyclo-[2.2.1]-heptylene compound has a great inhibitory activity on an MCF-7 cell in comparison to an existing anti-breast-cancer medicine tamoxifen.

The invention discloses an application of an ingenane diterpene compound in preparation of antitumor drug. The ingenane diterpene compound is one or more of the ingenane diterpene compound shown in a formula (1). The ingenane diterpene compound can obviously inhibit the propagation activity of breast cancer cells, compared with a traditional tumor therapeutic method, tumor inhibitory effect is good, toxic and side effects are little, targeting property is strong, the ingenane diterpene compound has no damage to normal cells, security can be guaranteed at maximum degree, the ingenane diterpene compound provides a latent novel medicine development purpose for treating breast cancer, and can be a further research as an anti-breast cancer candidate medicine.

The invention belongs to the technical field of medicine and discloses a preparation method of an oxygen bridge dicycloheptene compound containing a resveratrol group. One of a 3-(4-hydroxyphenyl)-4-(((E)-3, 5-dihydroxystyryl)phenyl)furan compound and a 3, 4-bis(4-hydroxy-phenyl)furan compound and one of a vinylsulfonate and a vinylsulfonate derivative as raw materials undergo a reaction without a catalyst at 90 DEG C for 8h to produce the oxygen bridge dicycloheptene compound containing a resveratrol group. The oxygen bridge dicycloheptene compound has an action method different from that of the existing anti-breast cancer drug tamoxifen. The oxygen bridge dicycloheptene compound can effectively inhibit growth of breast cancer cells MCF-7 and triple-negative breast cancer cells MDA-MB-231, has good anti-inflammatory activity and has an application prospect in breast cancer treatment.

The present invention discloses a coxsackievirus, which is a coxsackievirus group B type 3 mutant strain, wherein the genome site 2690 is adenine, and the genome site 3231 is guanine. The coxsackievirus has significant cytolytic capacity and selection specificity, can be used for preparation of anti-tumor drugs, especially anti-lung cancer drugs, anti-liver cancer drugs, anti-prostate cancer drugs, anti-melanoma drugs, anti-breast cancer drugs, anti-colon cancer drugs and anti-rectal cancer drugs, is used for preparation of anti-tumor drugs, and has characteristics of good anti-tumor effect and high safety.

The invention belongs to technical field of medicines and specifically relates to an oxygen bridge bis-heptylene sulfonamide compound containing a suberic acid monoanilide group as well as a synthesizing method, application and an anti-breast cancer drug composition of the oxygen bridge bis-heptylene sulfonamide compound. The oxygen bridge bis-heptylene sulfonamide compound containing the suberic acid monoanilide group is prepared by one-step reaction of the following raw materials: 3-(4-hydroxyphenyl)-4-suberic acid monoanilino-furan and an ethenyl sulfonamide derivative at the temperature of 90 DEG C for 3 without a solvent or a catalyst. The oxygen bridge bis-heptylene sulfonamide compound is different from the existing anti-breast cancer drug tamoxifen in action modes and is an anti-breast cancer compound acting on an estrogen receptor and histone histone deacetylase dual target sites.

The invention discloses an oxygen bridge bicyclo-[2.2.1]-heptene compound containing different functional side chain structures, as well as preparation and application thereof. The preparation comprises the following steps that furan derivatives which contain different functional side chain structures (2,3-glycol butyl, N,N-diethoxy ethylamino, 2-pyrrolidinyl ethyl, 2-piperidine ethyl and alkyl acid) and are synthesized from 3,4-bis(4-methyoxy-phenyl)furan reacts with vinyl sulfonamide derivatives at 90 DEG C for 12 hours in one step without solvent or catalyst to prepare the oxygen bridge bicyclo-[2.2.1]-heptene compound containing basic side chains and other functional side chain groups. In-vitro experiments indicate that, compared with an existing anti-breast cancer drug tamoxifen, thenovel sulfamide type oxygen bridge bicyclo-[2.2.1]-heptene compound has stronger inhibiting activity on MCF-7 cells, and has excellent protein degrading activity and equivalent degrading performance as that of existing drug fulvestrant.

Theinvention provides an alkynyl containing ruthenium complex, and also relates to a synthesis method and application of the alkynyl-containing ruthenium complex. The alkynyl-containing ruthenium complex is a new type of ruthenium complex, and alkynyl is introduced into the DPPZ type ruthenium complex through Sonogashira coupling reaction, and is favorable for promoting the transmembrane absorption effect of drug molecules, improving the probability of drugs entering cells and enhancing the medical efficacy while lowering the toxic and side effects of the drugs. The alkynyl-containing ruthenium complex provided by the invention has significant anti-tumor activity, especially anti-breast cancer activity, provides a new idea for molecule design of future anti-tumor drugs, can also be used asa fluorescent probe, and thus has broad application prospects in the field of medicinal chemistry.

The invention discloses a multi-functional liposome having oxidation-reduction responsiveness and capable of reinforcing tissue permeation, and a preparation method and application of the multi-functional liposome. A disulfide bond mediated oxidation-reduction responsiveness DSPE-S-S-chemotherapeutic drug prodrug is modified on the surface of the liposome, a hydrophobic photosensitizer is loaded on a phospholipid bimolecular layer, and a hydrophilic drug capable of reinforcing tissue permeability is entrapped in a water phase in the liposome. The liposome prepared by the preparation method disclosed by the invention can release chemotherapeutic drugs in a manner of oxidation-reduction responsiveness, permeation of the liposome in tumor tissue and infiltration of the liposome in peripheraloxygen are reinforced, the liposome can be used as a pharmaceutical preparation capable of resisting breast cancer, resisting liver cancer, resisting lung cancer or resisting cervical cancer for treating tumors, and the effect of synergistically resisting the tumor with chemotherapy / photodynamic therapy is increased.

The invention discloses a preparation method and an application of a mung bean polypeptide having anticancer activity. The preparation method comprises the following steps: 1) taking mung beans, removing impurities, cleaning the mung beans, drying and milling the mung beans, and screening milled mung beans to obtain mung bean powder; 2) extracting proteins from the expanded mung bean powder by using an alkali extraction and acid precipitation technology or a physical technology, and drying the obtained protein sample; and 3) dissolving the protein sample obtained in step 2) in a PBS phosphoricacid buffer solution or distilled water in proportion, adding one or more digestive enzymes in proportion, performing hydrolysis, and drying the resulting hydrolysate to obtain mung bean polypeptide.The preparation method of the mung bean polypeptide is simple and is easy to operate. The mung bean polypeptide prepared by the preparation method has an anti-cancer effect, and especially has an anti-breast cancer effect.

The invention discloses a thiazole derivative represented by formula (I), and a synthesis method thereof. The thiazole derivative represented by formula (I) is synthesized through a reaction of an alpha-bromoenaminone compound and carbon disulfide used as raw materials in a solvent under the action of an alkali. Like compounds have good bioactivities, such as antibacterial activity and anti-breast cancer activity. The synthesis method has the advantages of simple and easily available raw materials, good universality, simple post-treatment, good yield and environmental protection. The invention also discloses an application of the thiazole derivative represented by formula (I) in the field of medicines.

The invention discloses a cholesterol derivative-modified multi-molybdenum oxygen cluster hybrid. The chemical formula of the cholesterol derivative-modified multi-molybdenum oxygen cluster hybrid is[(C4H9)4N]3{(MnMo6O18)[CNH(CH2O)3O72H116N3O8]2} and is shown as the structural formula (I), wherein POM=MnMo6O18, and TBA=[(C4H9)4N]+. The cholesterol derivative-modified multi-molybdenum oxygen cluster hybrid is prepared by taking a multi-molybdenum oxygen cluster with a chemical formula of [(C4H9)4N]3(MnMo6O18)[(OCH2)3CNH2]2, 3, 3'-dicholesterol succinyl imidazole monoester dipropyl amine succinate monoamide, 1-ethyl-(3-dimethyl aminopropyl) carbondiimide hydrochloride, N-hydroxysuccinimide and trimethylamine as raw materials for reaction in a chloroform-acetonitrile mixed solvent system. The cholesterol derivative-modified multi-molybdenum oxygen cluster hybrid is applied to preparation of anti-breast cancer drugs and achieves high killing effects on human breast adenocarcinoma cell lines (MCF-7).

The invention provides a 2,3-unsaturated galactopyranoside compound. The structural formula of the compound is shown in the specification, wherein R1 comprises any one of methylene carboxylate, benzyl, alkyl, phenyl, substituted phenyl and a five-membered or six-membered heterocyclic group, and the five-membered or six-membered heterocyclic group comprises 2-pyrimidinyl, 2-benzoxazole or imidazolyl; and R2 comprises any one of a silicon group, C1-C18 alkyl, benzyl, phenyl, triphenylmethyl, pyridyl, benzoate, pyridine acid ester and quinolinecarboxylic acid ester. A preparation method of the compound comprises the following steps: adding a catalyst, a ligand and galactulose into an organic solvent and a sugar acceptor, carrying out stirring reaction at room temperature, carrying out TLC detection on the reaction process, and terminating the reaction after the galactulose raw material completely disappears to obtain the 2,3-unsaturated galactopyranoside. The prepared 2,3-unsaturated galactopyranoside compound is applied to the preparation of drugs for resisting gastric cancer and breast cancer, and a remarkable effect is achieved.

The invention discloses an oxo-bridged bicyclo-heptylene sulfonamides compound containing different alkyl chain lengths, as well as a preparation method and application thereof, and belongs to the technical field of medicines. 3-(4-hydroxycyclohexyl phenyl)-4-(4-alkoxy phenyl)-furan and a phenylethylene sulfonamide derivative are adopted as raw materials, no catalyst is needed, the raw materials are reacted at 90 DEG C for 8 hours, and the oxo-bridged bicyclo-heptylene sulfonamides compound containing the different alkyl chain lengths is obtained through one-step preparation. The action mode of the oxo-bridged bicyclo-heptylene sulfonamides compound is different from the action mode of existing anti-breast cancer drug tamoxifen, and the compound not only can be used for effectively inhibiting the growth of a breast cancer cell MCF-7, but also has favorable estrogen receptor alpha down-regulation activity equivalent to fulvestrant, and shows an application prospect of the compound in breast cancer therapy.

The invention discloses a traditional Chinese medicine compound for resisting breast cancer metastasis and reoccurrence. The compound includes the following components by weight: 8-10 parts of radix bupleuri, 8-15 parts of radix paeoniae alba, 8-10 parts of angelica sinensis, 8-10 parts of rhizoma pinellinae praeparata, 8-10 parts of semen citri reticulatae, 8-10 parts of selfheal, 8-10 parts of thunberg fritillary bulb, 10-30 parts of raw oyster shell, 8-10 parts of fiveleaf akebia fruit, 5-10 parts of edible tulip, 8-10 parts of curcuma zedoary, 8-30 parts of raw coix seed, 8-10 parts of pangolin scale, 8-10 parts of nidus vespae, 9-15 parts of rhizoma amorphophalli, 8-10 parts of taxus chinensis and 3-6 parts of licorice root. A preparation method and the application of the traditional Chinese medicine are further disclosed. Aiming at the basic pathogenesis of 'lier constraint, fire transmission, phlegm and blood stagnation poison and qi-blood deficiency' of breast cancer metastasis and reoccurrence, the traditional Chinese medicine compound soothes liver-qi stagnation, dissolves phlegm and stasis, clearing heat and poison, reinforcing qi, nourishing blood, is capable of remarkably reducing breast cancer metastasis and reoccurrence and has exact effects clinically.

The invention relates to a preparation method and application of a prenylated flavonoid compound with anti-breast cancer activity, and can effectively solve the problem about preparation of anti-hepatoma medicine through preparation of the prenylated flavonoid compound with anti-breast cancer activity. The method comprises the following steps: extracting fructus podophylli with ethyl alcohol; recycling ethyl alcohol; suspending in distilled water; extracting with petroleum ether, dichloromethane, ethyl acetate and n-butyl alcohol; carrying out gradient elution on ethyl acetate extraction parts with petroleum ether-acetone; combining flow parts to obtain components Fr.1-Fr.16; eluting component Fr.4 with methyl alcohol, and eluting the obtained sub-component Fr.4-1 with methyl alcohol-water, so as to obtain sinoflavonoid O; eluting component Fr.5 with methyl alcohol, and eluting the obtained sub-component Fr.5-1 with methyl alcohol-water, so as to obtain sinoflavonoid J, sinoflavonoid K, sinoflavonoid M and sinoflavonoid N; eluting component Fr.6 with methyl alcohol, eluting the obtained sub-component Fr.6-1 with methyl alcohol-water, and eluting the obtained sub-component Fr.6-1-2 with methyl alcohol-water, so as to obtain sinoflavonoid L. The prenylated flavonoid compound has anti-breast cancer activity, and is used for preparing anti-breast cancer medicine.

The invention discloses a benzamide compound with antitumor activity as well as a preparation method and application thereof. The structural formula of the compound is shown in the specification, wherein in the structural formula, R1 is hydrogen or halogen; R2 is alkoxy with carbon number of 1-4; the terminal of R2 is replaced by tert-amido; R2 is linked to the para-position of benzamide via oxygen atoms; R3 is one of hydroxyl or methoxyl; R4 is the other one of hydroxyl or methoxyl. The compound has good tumor cell inhibiting activity in vitro and can be used for preparing antitumor drugs, especially anti-hepatoma drugs and anti-breast cancer drugs. The preparation method of the benzamide compound, provided by the invention, has the advantages that the raw materials are accessible, the reaction conditions are mild, the reaction process is simple to operate, and the used reagent is cheap.

The present invention provides a method for screening anti-breast cancer metastasis compounds by using a tumor metastasis gene map. The method comprises: randomly selecting at least one gene from 18 genes such as MMP1, FSCN1, PTGS2, EREG, ANGPTL4, VCAM1, CXCR4, CXCL1, RARRES3, ID1, TNC, LY6E, LTBP1, C10orf116, KRTHB1, KYNU, MAN1A1 and NEDD9; and designing probes, and selecting compounds for converting the expression levels of the genes in breast cancer cells after metastasis to the expression levels of the genes in in-situ carcinoma cells or normal cells. According to the present invention, the 20 compounds are selected through the method, and the cytological level and animal level experiment results demonstrate that the compounds or the combinations thereof exhibit the anti-breast cancermetastasis activity to different degrees.

The invention relates to an anti-breast cancer traditional Chinese medicine composition as well as a preparation method and application thereof. The active ingredients of the traditional Chinese medicine composition consist of prunella vulgaris and dandelion. In the invention, the prunella vulgaris and dandelion are combined to realize a synergistic effect thereof, and the effect of preventing and treating breast cancer is improved.

The invention belongs to the field of medicines, discloses a novel withanolides compound, a novel withanolides compound preparation method and a medical application of the novel withanolides compound and particularly relates to a novel withanolides compound obtained by separation from dried roots of attalanteae buxifoliae, a preparation method of the novel withanolides compound and a medical application of the novel withanolides compound. The novel withanolides compound which is reported for the first time can be obtained by separation and purification after extraction from the dried roots of attalanteae buxifoliae, and high purity is achieved. According to in-vitro tests, the novel withanolides compound with an effect of in-vitro resistance to breast cancers is capable of inhibiting proliferation of various breast cancer cells, shows high in-vitro cytotoxicity and can be further researched and developed for preparation of breast cancer treatment medicines.

The invention specifically relates to application of melittin in preparation of a drug used for inhibiting invasion metastasis of breast cancer cells, which belongs to the field of bioengineering technology. CD147 and MMP9 proteins exert significant effects on invasion and metastasis of breast cancer MCF-7 cells. The invention aims to find a CD147 expression inhibitor which is capable of hindering or reducing secretion of MMP9 and inhibiting invasion metastasis of cancer cells to cancerous peripheral tissue. According to the invention, MCF-7 cells are cultured at first, then different doses of melittin is used, and flow cytometry, ELISA and RT-PCR experimental results prove that expression of CD147 and MMP9 is suppressed in the MCF-7 cells treated by melittin; and then Transwell invasion chamber experiments are conducted to detect the migration rate of the MCF-7 cells treated by melittin. Melittin can inhibit invasion metastasis of the MCF-7 cells. Thus, a novel anti-breast cancer drug can be developed from melittin.

The invention discloses application of tipranavir to a breast cancer-resistant drug and the breast cancer-resistant drug. The tipranavir is used for preparing the breast cancer-resistant drug. The invention provides the breast cancer-resistant drug comprising the tipranavir. The tipranavir serves as a main active component for resisting the breast cancer. By using a computer virtual screening method, a molecule namely the tipranavir is selected, and the matching degree between the tipranavir and an SIRT1 active pocket is highest; the proliferation inhibition rate of breast cancer cells further reaches 82.10 percent after the cancer is treated by the tipranavir for 72 hours through the verification of a cell experiment; a flow cell experiment result shows that the tipranavir has an apoptosis-inducing effect on the breast cancer cells; an experiment result shows that the tipranavir can remarkably inhibit the activity of breast cancer tumor cells and has a broad application prospect.

The invention discloses a marked cyclofenil derivative as shown in formula IV, a referential compound and midbody thereof, a preparation method and an application, wherein m is equal to 0-9, n is equal to 0-6, 99mTc is 99m technetium, and CO is carbonyl group. The marked cyclofenil derivative in the invention has activity to resist breast cancer and has favorable visualization effect.